Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Recruiting · NCT06391892 · Interventional (participants receive a specific treatment) · Lead sponsor: Elisabethinen Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Neoadjuvant chemotherapy instead of upfront surgeryUpfront surgery
What this trial is about
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.
Who can take part
Age range
18 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Informed consent
- \>18 years old
- localized pancreatic cancer to go for upfront surgery
Exclusion criteria
- synchronous secondary malignancy
- pregnancy
Where it is running
1 location listed.
- Ordensklinikum Linz Barmherzige Schwestern - Linz, Upper Austria, Austria